Investors are logical people. They invest in medicines that they expect will give them a return.
Right now, there’s far too little investment in developing new antibiotics. The pipeline of treatment is thin, but the need is greater than ever.
Enter the AMR Action Fund.
Hear our conversation with Dr. Henry Skinner, Chief Executive Officer at AMR Action Fund about:
The increasing cost of AMR and policy challenges
How to build the pipeline to reach the new antibiotics we need to save millions
Leveraging healthcare innovation for AMR before it’s too late
AMR Action Fund’s first two investments and future outlook 


More information about Henry and today’s topics:
LinkedIn Profile: http://www.linkedin.com/in/henryskinner/
Company Website: https://www.amractionfund.com/ 


As we continue this journey together, we want to hear from you, the listener. Email [email protected] or [email protected] what’s top of mind, what story you want to hear, or what you find interesting!
To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.